Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endometrial cancer with positive sentinel lymph nodes: pathologic characteristics of metastases as predictors of extent of lymphatic dissemination and prognosis.
Dinoi G, Ghoniem K, Huang Y, Zanfagnin V, Cucinella G, Langstraat C, Glaser G, Kumar A, Weaver A, McGree M, Fanfani F, Scambia G, Mariani A. Dinoi G, et al. Among authors: zanfagnin v. Int J Gynecol Cancer. 2024 Apr 23:ijgc-2023-005181. doi: 10.1136/ijgc-2023-005181. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38658020
Minimally Invasive Compared With Open Surgery in High-Risk Endometrial Cancer: A Systematic Review and Meta-analysis.
Dinoi G, Ghoniem K, Murad MH, Segarra-Vidal B, Zanfagnin V, Coronado PJ, Kyrgiou M, Perrone AM, Zola P, Weaver A, McGree M, Fanfani F, Scambia G, Ramirez PT, Mariani A. Dinoi G, et al. Among authors: zanfagnin v. Obstet Gynecol. 2023 Jan 1;141(1):59-68. doi: 10.1097/AOG.0000000000004995. Epub 2022 Nov 30. Obstet Gynecol. 2023. PMID: 36701610
Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
Kanakkanthara A, Hou X, Ekstrom TL, Zanfagnin V, Huehls AM, Kelly RL, Ding H, Larson MC, Vasmatzis G, Oberg AL, Kaufmann SH, Mansfield AS, Weroha SJ, Karnitz LM. Kanakkanthara A, et al. Among authors: zanfagnin v. Cancer Res. 2022 Jan 15;82(2):307-319. doi: 10.1158/0008-5472.CAN-21-0732. Epub 2021 Nov 22. Cancer Res. 2022. PMID: 34810199 Free PMC article.
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.
Colon-Otero G, Zanfagnin V, Hou X, Foster NR, Asmus EJ, Wahner Hendrickson A, Jatoi A, Block MS, Langstraat CL, Glaser GE, Dinh TA, Robertson MW, Camoriano JK, Butler KA, Copland JA, Weroha SJ. Colon-Otero G, et al. Among authors: zanfagnin v. ESMO Open. 2020 Oct;5(5):e000926. doi: 10.1136/esmoopen-2020-000926. ESMO Open. 2020. PMID: 33109627 Free PMC article. Clinical Trial.
Sentinel Lymph Nodes and Precision Surgery in Gynecologic Cancer.
Ghoniem K, Shazly SA, Dinoi G, Zanfagnin V, Glaser GE, Mariani A. Ghoniem K, et al. Among authors: zanfagnin v. Clin Obstet Gynecol. 2020 Mar;63(1):12-23. doi: 10.1097/GRF.0000000000000517. Clin Obstet Gynecol. 2020. PMID: 31855904 Review.
23 results